Radiation-sparing managements for cervical cancer: a developing countries perspective

Table 1 Pathological complete response rates in trials of preoperative radiation or chemoradiation with and without brachytherapy.

# of pat	[ref]	EBRT+BT	EBRT/CT+BT	EBRT/CT no BT	path CR (%)
66	[55]	37.4-40Gy+20Gy			69
61	[56]	46Gy CDDP+27Gy			44
360	[57]	20Gy+40Gy			48
168	[58]	45Gy+30Gy			41
123	[51]	45Gy+30Gy			48
					Mean (50.0%)
20	[59]		45Gy CDDP/5FU+20Gy		60
43	[57]		45Gy CDDP+15Gy		63
35	[60]		45Gy CDDP/5FU+20Gy		45
175	[58]		45Gy CDDP+30Gy		52
112	[61]		45Gy CDDP/FU+15Gy		49
175	[62]		44Gy CDDD+16Gy		38
					Mean (51.1%)
30	[63]			45Gy CDDP/5FU	46.6
100	[64]			39Gy CDDP/5FU	45.2
24	[53]			39Gy CDDP/5FU	54.2
40	[70]			50Gy CDDP	45
40	[70]			50Gy CDDP/GEM	67
					Mean (51.6%)

Most patients were IB2-IIA, some included IIB. Trials whose definition of complete pathological response encompased microscopic residual disease were not accounted.

ISSN: 1477-7819